Aligos Therapeutics, Inc.
ALGS
$10.10
$0.25992.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -136.82% | 152.45% | -326.55% | -480.54% | 114.52% |
| Total Depreciation and Amortization | 33.51% | -71.09% | 0.60% | 160.55% | -9.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.62% | -195.10% | 3,693.54% | 105.78% | -266.89% |
| Change in Net Operating Assets | 124.25% | -883.33% | 87.74% | -177.40% | 174.83% |
| Cash from Operations | 25.85% | -13.62% | 8.45% | -3.12% | 14.30% |
| Capital Expenditure | -153.49% | -53.57% | -7.69% | -271.43% | 89.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.70% | -320.12% | 91.86% | -73.94% | 145.16% |
| Cash from Investing | 10.54% | -320.64% | 92.08% | -74.00% | 145.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -760.00% | 68.75% | 15.79% |
| Issuance of Common Stock | -- | 72,572.86% | 13,900.00% | -99.66% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.17% | 104,788.66% | 2,525.00% | -101.42% | 1,578.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -249.87% | 2,106.84% | 117.16% | -146.71% | 118.65% |